First Trust Advisors LP Decreases Stake in Halozyme Therapeutics, Inc. $HALO

First Trust Advisors LP cut its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 765,918 shares of the biopharmaceutical company’s stock after selling 37,776 shares during the period. First Trust Advisors LP owned approximately 0.62% of Halozyme Therapeutics worth $39,843,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in HALO. Redhawk Wealth Advisors Inc. increased its position in shares of Halozyme Therapeutics by 14.8% during the 2nd quarter. Redhawk Wealth Advisors Inc. now owns 37,419 shares of the biopharmaceutical company’s stock valued at $1,947,000 after purchasing an additional 4,827 shares during the last quarter. Intech Investment Management LLC boosted its stake in Halozyme Therapeutics by 9.9% during the first quarter. Intech Investment Management LLC now owns 153,199 shares of the biopharmaceutical company’s stock worth $9,776,000 after buying an additional 13,789 shares during the period. Norges Bank bought a new position in Halozyme Therapeutics during the second quarter valued at $45,027,000. Boston Partners raised its stake in shares of Halozyme Therapeutics by 7.9% in the second quarter. Boston Partners now owns 449,366 shares of the biopharmaceutical company’s stock valued at $23,999,000 after acquiring an additional 33,041 shares during the period. Finally, Focus Partners Wealth lifted its holdings in shares of Halozyme Therapeutics by 57.8% in the 1st quarter. Focus Partners Wealth now owns 120,815 shares of the biopharmaceutical company’s stock worth $7,709,000 after acquiring an additional 44,260 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Activity

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $68.48, for a total value of $136,960.00. Following the transaction, the director owned 42,952 shares in the company, valued at $2,941,352.96. The trade was a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares of the company’s stock, valued at $55,285,726.65. This represents a 2.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 83,625 shares of company stock worth $5,932,527. 2.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Benchmark increased their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Leerink Partnrs raised Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 14th. HC Wainwright reissued a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research note on Friday, November 28th. Wall Street Zen downgraded Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, JPMorgan Chase & Co. increased their target price on Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research note on Monday, October 27th. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $75.10.

Halozyme Therapeutics Trading Down 1.6%

NASDAQ:HALO opened at $61.87 on Wednesday. The firm has a 50-day simple moving average of $67.74 and a 200-day simple moving average of $64.53. Halozyme Therapeutics, Inc. has a one year low of $46.26 and a one year high of $79.50. The firm has a market cap of $7.28 billion, a P/E ratio of 13.03, a P/E/G ratio of 0.34 and a beta of 0.95. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. The firm had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The company’s quarterly revenue was up 22.1% on a year-over-year basis. During the same period last year, the firm earned $1.27 earnings per share. Equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.